1314945-87-3

Basic information

• Product Name: (R)-1-[1-(2-cyano-benzyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-7-yl]pyrrolidin-3-yl tert-butyl carbamate
• CAS NO: 1314945-87-3
• Molecular Weight: 448.525
• Mol File: 1314945-87-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: (R)-1-[1-(2-cyano-benzyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-7-yl]pyrrolidin-3-yl tert-butyl carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-[1-(2-cyano-benzyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-7-yl]pyrrolidin-3-yl tert-butyl carbamate(1314945-87-3)
• EPA Substance Registry System: (R)-1-[1-(2-cyano-benzyl)-3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin-7-yl]pyrrolidin-3-yl tert-butyl carbamate(1314945-87-3)

Safety Data

• Hazardous Substances Data: 1314945-87-3(Hazardous Substances Data)

Upstream product

• 1314945-75-9 (R)-1-(2-chloro-3-nitropyridin-4-yl)pyrrolidin-3-yl tert-butyl carbamate 
• 1314945-84-0 (R)-1-(3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-7-yl)pyrrolidin-3-yl tert-butyl carbamate 
• 22115-41-9 2-(bromomethyl)benzonitrile 
• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 

Downstream Products

• 1314943-93-5 (R)-2-[[7-(3-aminopyrrolidin-1-yl)-3-methyl-2-oxo-2,3-dihydroimidazo[4,5-b] pyridin-1-yl]methyl]benzonitrile trifluoroacetate 

Relevant articles and documents

Discovery of imigliptin, a novel selective DPP-4 inhibitor for the treatment of type 2 diabetes

We report our discovery of a novel series of potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors. Starting from a lead identified by scaffold-hopping approach, our discovery and development efforts were focused on exploring structure-activity relationships, optimizing pharmacokinetic profile, improving in vitro and in vivo efficacy, and evaluating safety profile. The selected candidate, Imigliptin, is now undergoing clinical trial.

FUSED PYRIDINE DERIVATIVES

Fused pyridine derivatives shown as the general formula (I), and their pharmaceutically acceptable salts, stereoisomers or solvates thereof are disclosed, which belong to the technical field of medicines. The R1, R2, R3, Q, X and Y substituents in formula (I) are defined as in the description. Also disclosed are the preparation methods, pharmaceutical compositions comprising the compounds and uses of the compounds in the manufacture of the medicine for the treatment and/or prevention of noninsulin-dependent diabetes, hyperglycemia, hyperlipidemia and insulin resistance.